A Dual-Sensor-Based Screening System for In Vitro Selection of TDP1 Inhibitors
Ann-Katrine Jakobsen,
Josephine Geertsen Keller,
María Gonzalez,
Endika Martin-Encinas,
Francisco Palacios,
Concepcion Alonso,
Birgitta Ruth Knudsen,
Magnus Stougaard
Affiliations
Ann-Katrine Jakobsen
Department of Pathology, Aarhus University Hospital, N 8200 Aarhus, Denmark
Josephine Geertsen Keller
Department of Clinical Medicine, Aarhus University, N 8200 Aarhus, Denmark
María Gonzalez
Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
Endika Martin-Encinas
Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
Francisco Palacios
Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
Concepcion Alonso
Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of Basque Country (UPV/EHU), 01006 Vitoria-Gasteiz, Spain
Birgitta Ruth Knudsen
Department of Molecular Biology and Genetics, Aarhus University, C 8000 Aarhus, Denmark
Magnus Stougaard
Department of Pathology, Aarhus University Hospital, N 8200 Aarhus, Denmark
DNA sensors can be used as robust tools for high-throughput drug screening of small molecules with the potential to inhibit specific enzymes. As enzymes work in complex biological pathways, it is important to screen for both desired and undesired inhibitory effects. We here report a screening system utilizing specific sensors for tyrosyl-DNA phosphodiesterase 1 (TDP1) and topoisomerase 1 (TOP1) activity to screen in vitro for drugs inhibiting TDP1 without affecting TOP1. As the main function of TDP1 is repair of TOP1 cleavage-induced DNA damage, inhibition of TOP1 cleavage could thus reduce the biological effect of the TDP1 drugs. We identified three new drug candidates of the 1,5-naphthyridine and 1,2,3,4-tetrahydroquinolinylphosphine sulfide families. All three TDP1 inhibitors had no effect on TOP1 activity and acted synergistically with the TOP1 poison SN-38 to increase the amount of TOP1 cleavage-induced DNA damage. Further, they promoted cell death even with low dose SN-38, thereby establishing two new classes of TDP1 inhibitors with clinical potential. Thus, we here report a dual-sensor screening approach for in vitro selection of TDP1 drugs and three new TDP1 drug candidates that act synergistically with TOP1 poisons.